Eptifibatide is a glycoprotein IIa/IIIb (Gb IIa/IIIb) inhibitor used in the treatment of ACS.[1–5] The use of Gb IIa/IIIb inhibitors has been reported to cause profound thrombocytopenia.[6] Most studies categorized thrombocytopenia as mild (platelet counts < 100,000/μL), severe (platelet counts < 50,000/μL), and profound with counts < 20,000/μL).[6] Abciximab, a Gb IIa/IIIb inhibitor, is known to cause thrombocytopenia. The gene discussed is ITGB1; the disease is Thrombocytopenia.